Moleculin Biotech, Inc.
MBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $21 | $29 | $0 | $31 |
| Gross Profit | -$21 | -$29 | $0 | -$31 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,738 | $3,600 | $3,435 | $4,455 |
| G&A Expenses | $0 | $2,091 | $2,477 | $0 |
| SG&A Expenses | $2,147 | $2,091 | $2,477 | $2,157 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $31 | $0 |
| Operating Expenses | $5,885 | $5,691 | $5,943 | $6,612 |
| Operating Income | -$5,906 | -$5,720 | -$5,943 | -$6,643 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$19,493 | -$1,920 | -$493 | $4,761 |
| Pre-Tax Income | -$25,399 | -$7,640 | -$6,436 | -$1,882 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25,399 | -$7,640 | -$6,436 | -$1,882 |
| % Margin | – | – | – | – |
| EPS | -17 | -12.25 | -1,722 | -14 |
| % Growth | -38.8% | 99.3% | -12,200% | – |
| EPS Diluted | -17 | -12.25 | -1,722 | -14 |
| Weighted Avg Shares Out | 1,492 | 621 | 4 | 135 |
| Weighted Avg Shares Out Dil | 1,492 | 621 | 4 | 135 |
| Supplemental Information | – | – | – | – |
| Interest Income | $39 | $26 | $30 | $47 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $21 | $29 | $31 | $31 |
| EBITDA | -$25,378 | -$7,611 | -$5,912 | -$1,851 |
| % Margin | – | – | – | – |